Treatment of Coagulopathy in Intracranial Hemorrhage

Current Treatment Options in Neurology

Volumn 12, Issue 2, 2010, Pages 113-128

  Aguilar, Maria I ^a   Freeman, William D ^a  

^a MAYO CLINIC HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CLOPIDOGREL; DABIGATRAN; EPTIFIBATIDE; FIBRINOLYTIC AGENT; FONDAPARINUX; FRESH FROZEN PLASMA; FUROSEMIDE; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MANNITOL; PHYTOMENADIONE; PRASUGREL; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TICLOPIDINE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; VITAMIN K GROUP; WARFARIN;

BLOOD CLOTTING DISORDER; BRAIN HEMORRHAGE; BRAIN INJURY; CLINICAL FEATURE; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEVER; FIBRINOLYTIC THERAPY; GLUCOSE BLOOD LEVEL; HUMAN; HYDROCEPHALUS; HYPERTENSION; INTENSIVE CARE UNIT; INTRACRANIAL HYPERTENSION; INTRACRANIAL PRESSURE; NEUROSURGERY; OXYGENATION; REVIEW; SEIZURE;

EID: 77953539468     PISSN: 10928480     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11940-010-0061-1     Document Type: Review

References (83)

1. Anderson CS, Chakera TM, Stewart-Wynne EG, Jamrozik KD: Spectrum of primary intracerebral haemorrhage in Perth, Western Australia, 1989-1990: incidence and outcome. J Neurol Neurosurg Psychiatry 1994, 57:936-940.
2. Broderick JP, Brott T, Tomsick T, et al.: Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. J Neurosurg 1993, 78:188-191.
3. Counsell C, Boonyakarnkul S, Dennis M, et al.: Primary intracerebral haemorrhage in the Oxfordshire community stroke project, 2: prognosis. Cerebrovasc Dis 1995, 5:26-34.
4. Brott T, Broderick J, Kothari R, et al.: Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke 1997, 28:1-5.
5. Broderick JP, Brott TG, Duldner JE, et al.: Volume of intracerebral hemorrhage. A powerful and easy-touse predictor of 30-day mortality. Stroke 1993, 24:987-993.
6. Hart RG, Tonarelli SB, Pearce LA: Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke 2005, 36:1588-1593.
7. Toyoda K, Yasaka M, Nagata K, et al.: Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage. The Bleeding with Antithrombotic Therapy (BAT) Retrospective Study. Cerebrovasc Dis 2009, 27:151-159.
8. Brody DL, Aiyagari V, Shackleford AM, Diringer MN: Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2005, 2:263-267.
9. FreemanWD, Calvo P, Aduen JF, et al.: Recombinant factor VIIa for warfarin-related ICH: 50 patients [abstract 014]. Presented at the 4th Annual Meeting of the Neurocritical Care Society. Baltimore, MD; November 5, 2006.
10. Hart RG, Boop BS, Anderson DC: Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995, 26:1471-1477.
11. Fang MC, Chang Y, Hylek EM, et al.: Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004, 141:745-752.
12. Flaherty ML, Haverbusch M, Sekar P, et al.: Longterm mortality after intracerebral hemorrhage. Neurology 2006, 66:1182-1186.
13. Sjoblom L, Hardemark HG, Lindgren A, et al.: Management and prognostic features of intracerebral hemorrhage during anticoagulant therapy: a Swedish multicenter study. Stroke 2001, 32:2567-2574.
14. Cucchiara B, Messe S, Sansing L, et al.: Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 2008, 39:2993-2996.
15. Flaherty ML, Tao H, Haverbusch M, et al.: Warfarin use leads to larger intracerebral hematomas. Neurology 2008, 71:1084-1089.
16. Huttner HB, Schellinger PD, Hartmann M, et al.: Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006, 37(6):1465-1470.
17. Flaherty ML, Kissela B, Woo D, et al.: The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology 2007, 68:116-121.
18. Falk RH: Atrial fibrillation. N Engl J Med 2001, 344:1067-1078.
19. Aguilar MI, Hart RG, Kase CS, et al.: Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc 2007, 82:82-92. This article offers opinions from the experts in the field regarding management of W ICH.
20. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990, 323:1505-1511.
21. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993, 342:1255-1262.
22. Hart RG, Halperin JL, Pearce LA, et al.: Lessons from the stroke prevention in atrial fibrillation trials. Ann Intern Med 2003, 138:831-838.
23. Hart RG, Pearce LA, Aguilar MI: Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007, 146:857-867.
24. Smith NL, Psaty BM, Furberg CD, et al.: Temporal trends in the use of anticoagulants among older adults with atrial fibrillation. Arch Intern Med 1999, 159:1574-1578.
25. Schulman S, Beyth RJ, Kearon C, et al.: Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133:257S-298S. These evidence-based guidelines, nicely written, provide concise information. (Pubitemid 351892969)
26. Hylek EM, Evans-Molina C, Shea C, et al.: Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007, 115:2689-2696.
27. Goldstein LB, Simel DL: Is this patient having a stroke? JAMA 2005, 293:2391-2402.
28. Broderick J, Connolly S, Feldmann E, et al.: Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke 2007, 38:2001-2023. These are the most recent guidelines regarding management of ICH
29. Ecker RD, Wijdicks EF: Footprints of coagulopathy. J Neurol Neurosurg Psychiatry 2002, 73:534.
30. Ichikawa K, Yanagihara C: Sedimentation level in acute intracerebral hematoma in a patient receiving anticoagulation therapy: an autopsy study. Neuroradiology 1998, 40:380-382.
31. Laissy JP, Normand G, Monroc M, et al.: Spontaneous intracerebral hematomas from vascular causes. Predictive value of CT compared with angiography. Neuroradiology 1991, 33:291-295.
32. Berwaerts J, Robb OJ, Jeffers TA, Webster J: Intracerebral haemorrhages and oral anticoagulation in the north of Scotland. Scott Med J 2000, 45:101-104.
33. Yasaka M, Oomura M, Ikeno K, et al.: Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose. Ann Hematol 2003, 82:121-123.
34. Flibotte JJ, Hagan N, O'Donnell J, et al.: Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004, 63:1059-1064.
35. Yasaka M, Minematsu K, Naritomi H, et al.: Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003, 89:278-283.
36. Adjusted-dose warfarin versus low-intensity, fixeddose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996, 348:633-638.
37. ESPRIT: Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. Stroke 2003, 34:e45-e46.
38. Gullov AL, Koefoed BG, Petersen P: Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. Arch Intern Med 1999, 159:1322-1328.
39. Yamaguchi T: Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke 2000, 31:817-821.
40. Freeman WD, Aguilar MI: Management of warfarinrelated intracerebral hemorrhage. Expert Rev Neurother 2008, 8(2):271-290.
41. Flaherty ML, Adeoye O, Sekar P, et al.: The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage. Stroke 2009, 40:1738-1742.
42. Stafford DW: The vitamin K cycle. J Thromb Haemost 2005, 3:1873-1878.
43. Ansell J, Hirsh J, Dalen J, et al.: Managing oral anticoagulant therapy. Chest 2001, 119:22S-38S.
44. Fredriksson K, Norrving B, Stromblad LG: Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992, 23:972-977.
45. Yasaka M, Sakata T, Minematsu K, Naritomi H: Correction of INR by prothrombin complex con-centrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2002, 108:25-30.
46. Lacy CF, Armstrong LL, Goldman MP, Lance LL: Drug Information Handbook, edn 11. Hudson, OH: Lexi-Comp, Inc.; 2003.
47. Riegert-Johnson DL, Volcheck GW: The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol 2002, 89:400-406.
48. Fiore LD, Scola MA, Cantillon CE, Brophy MT: Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 2001, 11:175-183.
49. Goldstein JN, Thomas SH, Frontiero V, et al.: Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006, 37:151-155.
50. Lee SB, Manno EM, Layton KF, Wijdicks EF: Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology 2006, 67:1272-1274.
51. Schulman S: Clinical practice. Care of patients receiving long-term anticoagulant therapy. N Engl J Med 2003, 349:675-683.
52. Makris M, Greaves M, Phillips WS, et al.: Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997, 77:477-480.
53. Mayer SA, Brun NC, Begtrup K, et al.: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352:777-785.
54. Mayer SA, Brun NC, Begtrup K, et al.: Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008, 358:2127-2137.
55. Deveras RA, Kessler CM: Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate. Ann Intern Med 2002, 137:884-888.
56. FreemanWD, Brott TG, BarrettKM, et al.:Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc 2004, 79:1495-1500.
57. Earnshaw SR, Joshi AV, Wilson MR, Rosand J: Costeffectiveness of recombinant activated factor VII in the treatment of intracerebral hemorrhage. Stroke 2006, 37:2751-2758.
58. Ardelt AA, Arenberg S, Kulesza P, Streiff MB: Anticoagulation reversal in patients with intracerebral hemorrhage, a survey of Neurocritical Care Society members [abstract 053]. Abstracts from the 4th Annual Meeting of the Neurocritical Care Society. Baltimore, MD; 2006:240.
59. Hellstern P: Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res 1999, 95:S7-S12.
60. Hellstern P, Halbmayer WM, Kohler M, et al.: Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res 1999, 95:S3-S6.
61. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995, 333:1581-1587.
62. Derex L, Hermier M, Adeleine P, et al.: Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry 2005, 76:70-75.
63. Demchuk AM, Morgenstern LB, Krieger DW, et al.: Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999, 30:34-39.
64. Gebel JM, Brott TG, Sila CA, et al.: Decreased perihematomal edema in thrombolysis-related intracerebral hemorrhage compared with spontaneous intracerebral hemorrhage. Stroke 2000, 31:596-600.
65. Mahaffey KW, Granger CB, Sloan MA, et al.: Neurosurgical evacuation of intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: experience from the GUSTO-I trial. Global Utilization of Streptokinase and Tissueplasminogen activator (tPA) for Occluded Coronary Arteries. Am Heart J 1999, 138:493-499.
66. Hanger HC, Fletcher VJ, Wilkinson TJ, et al.: Effect of aspirin and warfarin on early survival after intracerebral haemorrhage. J Neurol 2008, 255:347-352.
67. Creutzfeldt CJ, Weinstein JR, Longstreth WT Jr, et al.: Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. J Stroke Cerebrovasc Dis 2009, 18:221-228.
68. Naidech AM, Jovanovic B, Liebling S, et al.: Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke 2009, 40:2398-2401.
69. Naidech AM, Bendok BR, Garg RK, et al.: Reduced platelet activity is associated with more intraventricular hemorrhage. Neurosurgery 2009, 65:684-688.
70. Naidech AM, Bassin SL, Bernstein RA, et al.: Reduced platelet activity is more common than reported antiplatelet medication use in patients with intracerebral hemorrhage. Neurocrit Care 2009, 11:307-310.
71. KobrinskyNL, Israels ED, Gerrard JM, et al.: Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1984, 1:1145-1148.
72. Demaerschalk BM, Aguilar MI: Treatment of acute intracerebral hemorrhage. Curr Treat Options Neurol 2008, 10:455-467.
73. Steiner T, Diringer MN, Schneider D, et al.: Dynamics of intraventricular hemorrhage in patients with spontaneous intracerebral hemorrhage: risk factors, clinical impact, and effect of hemostatic therapy with recombinant activated factor VII. Neurosurgery 2006, 59:767-773, discussion 773-774.
74. Sugg RM, Gonzales NR, Matherne DE, et al.: Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa. Neurology 2006, 67:1053-1055.
75. Fernandes HM, Gregson B, Siddique S, Mendelow AD: Surgery in intracerebral hemorrhage. The uncertainty continues. Stroke 2000, 31:2511-2516.
76. Mendelow AD, Gregson BA, Fernandes HM, et al.: Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematoma s in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 2005, 365:387-397. This is the largest surgical ICH trial to date.
77. DuncanPW, Zorowitz R, Bates B, et al.:Management of adult stroke rehabilitation care: a clinical practice guideline. Stroke 2005, 36:e100-e143.
78. Schulman S, Bijsterveld NR: Anticoagulants and their reversal. Transfus Med Rev 2007, 21(1):37-48.
79. Aiyagaru V: Correction of coagulopathy secondary to oral and parenteral anticoagulants. Continuum 2009, 15(3):138-157.
80. MathewsM, Newman R, Chappell ET: Management of coagulopathy in the setting of acute neurosurgical disease and injury. NeurocritCare 2006, 5(2):141-152.
81. Mannucci PM, Vicente V, Vianello L, et al.: Controlled trial of desmopressin (DDAVP) in the treatment of conditions associated with prolonged bleeding time. Blood 1986, 67:1148-1153.
82. Hillbom ME,Huhtakangas JT: Platelet transfusion in acute intracerebral hemorrhage. NCT 00699621. Available at ClinicalTrials.gov.
83. Kobinsky NL, Gergard JM, Watson CM, et al.: Shortening of bleeding time by 1-deamino-8-D-arginine vasopressin in various bleeding disorders. Lancet 1984, 323:1145-1148.